Stilbene-pyridazinone hybrids: design, synthesis and in vitro antiplatelet activity screening
- PMID: 38986420
- DOI: 10.1016/j.bioorg.2024.107615
Stilbene-pyridazinone hybrids: design, synthesis and in vitro antiplatelet activity screening
Abstract
A series of stilbene analogues, in which a phenyl ring was replaced by the pyridazin-3(2H)-one nucleus, was designed and synthesized to be explored as platelet aggregation inhibitors. The proposed stilbene-pyridazinone hybrids were successfully obtained from simple starting materials and by Wittig's reaction. Most of the target compounds displayed improved in vitro activity in comparison with the standard drug, resveratrol, highlighting as the most potent the analogues 10d and 10e, with inhibition percentages of 94.15 % at 100 µM and 100 % at 50 µM, respectively. The pharmacokinetic and toxicity (ADME/T) properties of the novel hybrids were also estimated with the SwissADME and ProTox-II web servers.
Keywords: Computational approach; Molecular hybridization; Platelets; Pyridazin-3(2H)-one; Stilbene; Synthesis; in vitro Study.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
